Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:  
The good — Pfizer advances once-daily obesity pill  
The bad — FDA rejects Novo Nordisk once-weekly insulin  
The ugly — FTC releases long-awaited report on PBMs

Genentech's oral weight loss drug shows promise; FDA denies accelerated approval for Agenus' cancer drug; Orexo's opioid overdose drug rejected again [The good, the bad, the ugly]

The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more